← back to search

Aiyun Wang

Nanjing University of Chinese Medicine · CN
Area of research
Cancer Research · Complementary and alternative medicine
Research interest
Research interests include PI3K/AKT/mTOR pathway, Autophagy, Glycolysis, Anaerobic glycolysis, Biology, and Cancer research.
h-index
—
citations
123
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗

Recent publications

Pharmacological manipulation of Ezh2 with salvianolic acid B results in tumor vascular normalization and synergizes with cisplatin and T cell-mediated immunotherapy
Pharmacological Research 2022cited by 56position: middledoi
Critical role of mTOR in regulating aerobic glycolysis in carcinogenesis (Review)
International Journal of Oncology 2020cited by 67position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Yin Lu · University of Science and Technology Beijing2 papers (2020–2022)Yang Zhao · Shenyang Pharmaceutical University1 papers (2022–2022)Weiwei Zheng · The University of Texas Southwestern Medical Center1 papers (2022–2022)Suyun Yu · Fudan University1 papers (2020–2020)Yuanyuan Wu · University of Science and Technology Beijing1 papers (2020–2020)Chunmei Yang · Nanjing University of Chinese Medicine1 papers (2022–2022)Zhonghong Wei · Nanjing University of Chinese Medicine1 papers (2022–2022)Chongjin Zhong · Nanjing University of Chinese Medicine1 papers (2022–2022)Yueke Zhou · Nanjing University of Chinese Medicine1 papers (2022–2022)Cheng Qian · Nanjing University of Chinese Medicine1 papers (2022–2022)Mengyao Song · Nanjing University of Chinese Medicine1 papers (2022–2022)Shan Zhang · Nanjing University of Chinese Medicine1 papers (2022–2022)Xiaoman Li · Nanjing University of Chinese Medicine1 papers (2020–2020)Li Wan · Jingzhou Central Hospital1 papers (2022–2022)Wenxing Chen · Nanjing University of Chinese Medicine1 papers (2020–2020)Hui Fan · Nanjing University of Chinese Medicine1 papers (2020–2020)Yu Tang · Jiangsu University1 papers (2022–2022)Shijun Wang · Fudan University1 papers (2020–2020)